Mark Schindel

Mark Schindel General Information

Biography

Mr. Mark Schindel serves as Executive In Residence at IU Ventures. He served as Chief Executive Officer at Owl Manor. He served as the Global Director of Marketing, SportsMed and Biologics at Tornier. He serves as Executive-in-Residence at Boomerang Ventures. He has broad international experience in the medical device (Biomet, Zimmer, Tornier), pharmaceutical/biotech (Roche), life-science (Vanderbilt University Tech Transfer) and Government (US DOE/Battelle) sectors. his expertise spans marketing, sales, brand/product management, project management, R&D, clinical, and business development (M&A, licensing). Specific to medical devices, he has worked across craniomaxillofacial, pediatrics, plastic surgery, cardiothoracic/cardiovascular, hips, knees, shoulders, foot and ankle and regenerative medicine. Products have ranged from pre-operative technologies to implants (including biologics, synthetics and xenografts) and delivery technologies (robotics, patient-specific instruments, computer-assisted surgery, injectables, disposables, etc.). As an entrepreneur, he served as CEO, Co-founder, and Board Member for Owl Manor Medical, LLC, an animal health biologics/medical device company with a focused regenerative medicine portfolio targeting equine and companion animal joint and soft tissue preservation. Following a successful Series A financing round, Owl Manor grew in revenues and profitability through its globally recognized portfolio. In addition to building a direct U.S./Canada sales channel, Owl Manor established a successful international business through a combination of distribution and direct sales across Europe, the Middle East, Australia, and Mexico. Founded in February 2015, Owl Manor was acquired on June 1, 2021, by Zoetis, the World's Largest Animal Health company. He holds an MBA from Vanderbilt University and a B.S. with honors from Purdue University.